Avelumab: all 201 studies that test it

Page 1 of 3. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial CarcinomaNot yet recruitingNCT07460245Phase 2
• Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCRecruitingNCT07225374Phase 2
• DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingNCT07110038Phase 2
• Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial CancerRecruitingNCT06892860Phase 2
• Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.RecruitingNCT06869473Phase 2
• Avelumab and M1774 in ARID1A-mutated Endometrial CancerRecruitingNCT06518564Phase 2
• Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)RecruitingNCT06228066Phase 2
• Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1
• Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial CancerRecruitingNCT05600127Phase 2
• CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge StrategyRecruitingNCT05291156Phase 2
• TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial CarcinomaRecruitingNCT04678362Phase 2
• Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line TreatmentRecruitingNCT04396223Phase 1/2
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
• Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaRecruitingNCT03787602Phase 1/2
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2Results posted
• Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular CarcinomaTerminatedNCT05249569Phase 2Results posted
• Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)TerminatedNCT04871529Phase 2Results posted
• Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyActive, not recruitingNCT04637594Phase 3Results posted
• Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaTerminatedNCT04322643Phase 2Results posted
• Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid TumorsActive, not recruitingNCT04266912Phase 1/2Results posted
• A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyActive, not recruitingNCT04215146Phase 2Results posted
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)CompletedNCT04173507Phase 2Results posted
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal CarcinomaTerminatedNCT04150562Phase 2Results posted
• Talazoparib and Avelumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT04068831Phase 2Results posted
• Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaCompletedNCT03990571Phase 2Results posted
• Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple MyelomaTerminatedNCT03910439Phase 2Results posted
• Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell MalignanciesCompletedNCT03905135Phase 1Results posted
• Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder CancerCompletedNCT03892642Phase 1/2Results posted
• QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyTerminatedNCT03853317Phase 2Results posted
• Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal AdenocarcinomasCompletedNCT03783936Phase 2Results posted
• Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPCTerminatedNCT03770455Phase 2Results posted
• Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell CancerTerminatedNCT03747484Phase 1/2Results posted
• Avelumab and Radiation in Muscle-Invasive Bladder CancerTerminatedNCT03747419Phase 2Results posted
• Study of Avelumab-M3814 CombinationsCompletedNCT03724890Phase 1Results posted
• Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLCCompletedNCT03717155Phase 2Results posted
• Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian CancerCompletedNCT03704467Phase 1Results posted
• A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid TumorsTerminatedNCT03637491Phase 1/2Results posted
• Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerCompletedNCT03617913Phase 2Results posted
• QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedNCT03586869Phase 1/2Results posted
• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid TumorsTerminatedNCT03565991Phase 2Results posted
• Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum ChemotherapyCompletedNCT03558139Phase 1Results posted
• Phase I/Ib Multiple Ascending Dose Study in ChinaCompletedNCT03523390Phase 1Results posted
• A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer PatientsTerminatedNCT03502681Phase 1Results posted
• A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder CancerTerminatedNCT03498196Phase 1/2Results posted
• A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)TerminatedNCT03472560Phase 2Results posted
• Phase I/II Study of Avelumab in Pediatric Cancer ParticipantsTerminatedNCT03451825Phase 1Results posted
• The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerActive, not recruitingNCT03414658Phase 2Results posted
• Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant MesotheliomaCompletedNCT03399552Phase 1/2Results posted
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
• QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedNCT03387111Phase 1/2Results posted
• QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03387098Phase 1/2Results posted
• QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedNCT03387085Phase 1/2Results posted
• Survival Prolongation by Rationale Innovative GenomicsTerminatedNCT03386929Phase 1/2Results posted
• Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic CancerTerminatedNCT03344172Phase 2Results posted
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsTerminatedNCT03330405Phase 1/2Results posted
• QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03329248Phase 1/2Results posted
• Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced MalignanciesTerminatedNCT03317496Phase 1/2Results posted
• Anti-PD-L1 and SAbR for Ovarian CancerTerminatedNCT03312114Phase 2Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)CompletedNCT03289533Phase 1Results posted
• PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate CancerCompletedNCT03179410Phase 2Results posted
• Palbociclib After CDK and Endocrine Therapy (PACE)Active, not recruitingNCT03147287Phase 2Results posted
• QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03136406Phase 1/2Results posted
• Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT03074318Phase 1/2Results posted
• Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004TerminatedNCT03050814Phase 2Results posted
• SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03050554Phase 1/2Results posted
• Avelumab in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT03047473Phase 2Results posted
• Avelumab in Relapsed and Refractory Peripheral T-cell LymphomaCompletedNCT03046953Phase 2Results posted
• A Phase II Trial of Avelumab in Patients With Recurrent or Progressive OsteosarcomaCompletedNCT03006848Phase 2Results posted
• Safety and Efficacy of Avelumab in Small Intestinal AdenocarcinomaTerminatedNCT03000179Phase 2Results posted
• A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)TerminatedNCT02994953Phase 1Results posted
• Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant GlioblastomaCompletedNCT02968940Phase 2Results posted
• Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02953561Phase 1/2Results posted
• Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)TerminatedNCT02952586Phase 3Results posted
• Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)TerminatedNCT02951156Phase 3Results posted
• Avelumab for Recurrent/Metastatic Nasopharyngeal CancerTerminatedNCT02875613Phase 2Results posted
• Avelumab for People With Recurrent Respiratory PapillomatosisCompletedNCT02859454Phase 2Results posted
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)TerminatedNCT02718417Phase 3Results posted
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)CompletedNCT02684006Phase 3Results posted
• Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)CompletedNCT02625610Phase 3Results posted
• A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)CompletedNCT02603432Phase 3Results posted
• Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)TerminatedNCT02603419Phase 1Results posted
• A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)CompletedNCT02580058Phase 3Results posted
• Avelumab in First-line NSCLC (JAVELIN Lung 100)CompletedNCT02576574Phase 3Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)CompletedNCT02493751Phase 1Results posted
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)CompletedNCT02395172Phase 3Results posted
• Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)CompletedNCT02155647Phase 2Results posted
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)CompletedNCT01943461Phase 1Results posted
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)CompletedNCT01772004Phase 1Results posted
• Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)WithdrawnNCT06424717Phase 2
• Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruitingNCT05947500Phase 2
• Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder CancerWithdrawnNCT05687721Phase 1/2
• Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline TherapyWithdrawnNCT05574504Phase 2
• GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric CancerCompletedNCT05419362Phase 2
• Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)CompletedNCT05289856Phase 2
• Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active, not recruitingNCT05222932Phase 1
• FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRCCompletedNCT05217069Phase 2
• Avelumab, Palbociclib and Axitinib in Advanced RCCWithdrawnNCT05176288Phase 2
• Study of MRx0518 and Avelumab in Patients With Urothelial CarcinomaWithdrawnNCT05107427Phase 2

← Avelumab overview